Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Pancragen

Lys-Glu-Asp-Trp, KEDW

A synthetic tetrapeptide bioregulator that may support pancreatic function, glucose metabolism, and endocrine regulation in aging.

Quick Stats
Studies 7
Trials 18
Formula C26H36N6O9
Clear All
Utility 3
pubmed 2014

[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].

Goncharova. N D ND; Ivanova. L G LG; Oganian. T É TÉ; Vengerin. A A AA; Khavinson. V Kh VK...

In older female rhesus monkeys, a short 10‑day course of the tiny peptide pancragen (Lys‑Glu‑Asp‑Trp) given by injection helped the pancreas work better: the monkeys cleared sugar from the blood faster and had more normal insulin and C‑peptide spikes after a glucose drink. Some of the benefit stuck around for a few weeks after stopping the peptide.

Utility 3
pubmed 2012

[Tetrapeptide stimulates functional activity of the pancreatic cells in aging].

Khavinson. V Kh VKh; Sevost'ianova. N N NN; Durnova. A O AO; Lin'kova. N S NS; Tarnovskaia. S I SI;...

A tiny four‑amino‑acid peptide (H‑Lys‑Glu‑Asp‑Trp‑NH2, called pancragen) was shown in lab cells from older people to boost markers of pancreatic cell health and reduce a protein that promotes cell death. The researchers say this could explain why older diabetics who took the peptide felt better, but they don’t give dosing or safety details.

Utility 3
pubmed 2015

[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys].

Goncharova. N D ND; Ivanova. L G LG; Oganyan. T E TE; Vengerin. A A AA; Khavinson. V Kh VK

In a small study with old female rhesus monkeys, a short‑acting tetrapeptide called Pancragen lowered fasting blood sugar and helped bring insulin and C‑peptide levels back to normal, suggesting it can improve age‑related glucose tolerance. Compared with the diabetes drug glimepiride, Pancragen gave a steadier drop in glucose without the delayed, stronger hypoglycemia seen with the drug.

Utility 3
pubmed Aug 17, 2011

Prospects of using pancragen for correction of metabolic disorders in elderly people.

Korkushko. O V OV; Khavinson. V Kh VKh; Shatilo. V B VB; Antonyk-Sheglova. I A IA; Bondarenko. E V E...

In older people with type‑2 diabetes, nighttime melatonin was much lower than in healthy peers. Giving the tetrapeptide pancragen lowered fasting blood sugar, improved glucose tolerance, and reduced insulin and insulin‑resistance markers, while people who didn’t get the peptide saw no change. The authors suggest that fixing melatonin‑related problems with pancragen might help older adults combat insulin resistance.

Utility 2
pubmed Oct 1, 2007

Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.

Khavinson. V Kh VKh; Gavrisheva. N A NA; Malinin. V V VV; Chefu. S G SG; Trofimov. E L EL

In a rat study, the short peptide pancragen lowered blood sugar when taken by mouth and helped protect tiny blood vessels in the gut when injected into muscle. It didn't change how leaky those vessels were, but it did improve the way the vessel walls stuck together. The work suggests the peptide might have blood‑sugar‑lowering and blood‑vessel‑protecting effects early in diabetes, but it’s only been tested in animals.

Utility 2
pubmed Feb 1, 2013

Effects of pancragen on the differentiation of pancreatic cells during their ageing.

Khavinson. V Kh VKh; Durnova. A O AO; Polyakova. V O VO; Tolibova. G H GH; Linkova. N S NS; Kvetnoy....

A lab study found that the tiny peptide pancragen can boost the activity of genes that help pancreatic cells stay youthful and function properly, even in older cell cultures. This suggests it might help protect against diabetes and inflammation, but the work was done only in petri dishes, not in people.

Utility 1
pubmed Aug 17, 2010

Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide.

Khavinson. V Kh VKh; Gapparov. M M-G MM; Sharanova. N E NE; Vasilyev. A V AV; Ryzhak. G A GA

The paper examined a naturally occurring four‑amino‑acid peptide (Lys‑Glu‑Asp‑Trp‑NH2) in developing animals and in a rat model of diabetes that mimics rapid aging. Researchers measured a bundle of metabolic markers linked to cell death (apoptosis) to see if the peptide had any protective or harmful effects. The study is very basic and does not provide dosing, safety, or clear performance benefits for humans.